Timothy w. synold
Professor
CANCER BIOLOGY
Beckman Research Institute
United States of America
Biography
Dr. Synold is a clinical and molecular pharmacologist who serves as Director of the Analytical Pharmacology and Clinical Immunology Laboratories. He is also the Scientific Leader of the COH Phase I Clinical Trial team and Director of Pharmacology for the NCI-supported California Cancer Consortium (CCC). Dr. Synold has over 25 years experience in chemistry and pharmacology, and he is an expert in the fields of pharmacokinetics and pharmacodynamics. His current research focus involves the role of the blood-brain-barrier in CNS penetration of drugs
Research Interest
Cancer Biology Analytical Pharmacology Core Phase I Disease Team CNS Malignancies Disease Team
Publications
-
National Cancer Institute Organ Dysfunction Working Group. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study
-
Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE. A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proceedings of the National Academy of Sciences. 2009 Mar 31;106(13):5394-9.
-
Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature medicine. 2001 May 1;7(5):584.
